Systematic Financial Management LP increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,278 shares of the specialty pharmaceutical company’s stock after purchasing an additional 794 shares during the period. Systematic Financial Management LP owned approximately 0.19% of Jazz Pharmaceuticals worth $13,618,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of JAZZ. Machina Capital S.A.S. bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $29,000. Signaturefd LLC grew its stake in Jazz Pharmaceuticals by 56.3% during the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 72 shares during the last quarter. Captrust Financial Advisors grew its stake in Jazz Pharmaceuticals by 120.0% during the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 120 shares during the last quarter. Stonebridge Capital Advisors LLC bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $37,000. Finally, AdvisorNet Financial Inc bought a new stake in Jazz Pharmaceuticals during the third quarter worth about $37,000. 87.74% of the stock is owned by hedge funds and other institutional investors.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at $40,541,150. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.
Shares of JAZZ traded up $1.45 during mid-day trading on Tuesday, hitting $132.33. 406,400 shares of the company traded hands, compared to its average volume of 550,702. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $154.44. The company has a current ratio of 3.89, a quick ratio of 3.71 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average of $124.79 and a 200 day moving average of $131.73. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 1.02 and a beta of 1.09.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The business had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. During the same period in the prior year, the firm earned $3.58 earnings per share. Jazz Pharmaceuticals’s revenue was up 14.6% compared to the same quarter last year. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 14.13 earnings per share for the current year.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: What is an overbought condition?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.